Member Info for Brand

Has anyone worked out the hazard ratio of progression to severe disease or death vs placebo when including the new numbers? Was it aproxx the same at 37%?

(Sorry if it's been posted and I missed it)

Thank you Tommy. Much appreciated.

I think the question raised 'is there precedent for this' is very relevant. Tbh I have no idea if it is, but I do know that the situation is unprecedented.

Considering the situation with covid, is there a thereputic that had been more trialed - vs more varients - than SNG001?

And would like to try adding the cohort from Mondays RNS to the per protocol cohort from sprinter, then apply the fisher method and tell us the hazard ratio and P value?

Lots of clever folks on here....

Re the interview with Ray, transcript below:

(He was certainly right about the focus shifting to PASC)

Ray Jordan - Video28 Feb 2022 22:52
Ray Jordan, big pharma PR heavy hitter, most recently of Moderna and currently consulting SNG (according to a press release on Fri Feb 18th) made an appearance on a podcast on Thurs and very much looked to allude to Synairgen on two occasions.

The live broadcast started at 4pm GMT, so both references were made after the market closed.

The two moments in question, transcribed below:

41.10m

"I'm sorry to interrupt but that triggered a thought for me, about the role of strategic planning, and the partnership between strategic planners and communication. I'm not active with moderna now from a consulting point of view in terms of what's next, but with another client we've been looking at COVID-19 from a thereputics point of view....

Now that vaccines have been very well promulgated, what are the oppurt- what are the issues w long covid? The sequele from the virus, the medical situations that come from the virus, loss of smell, cardiovascular situations, right.

So well It is possible from a true business planning point of view to look in to the post-covid world

And I think there's, I would encourage communicators within their own enterprises, what's being looked at from a business prospect point of view

Cause I have found that the media is getting increasingly bored of covid in terms of vaccinating people, but much more intrigued by the question of 'wheres long covid going?' How are treatments going to be made available for the problems people face from it?"

101.00m

"On the question of the CCO impact, especially in companies that have had a direct involvement, ive actually seen, like with the thereputic company that I'm engaged with now, the recognition is that CCO has made such a difference in the Pandemic environment, by being able to reach out to the stakeholders and so much has been done in the sort of earned media environment and in the communicating with partners and employees, I don't think that's going to fade away, I think actually it's a recognition of the power there."

This is the link but you may need to register

https://www.conference-board.org/webcast/ondemand/cco-reflections

I'm not going to speculate as to what to interpret from his comments, but I'm pleased he's working with the company

Ray Jordan is the type of bloke that can bend a lot of ears in DC. Exactly the type of heavy hitter you would need to break through the big pharma juggernaut.

The big question with big ray and SNG is, was he the last play of of bullish pre-sprinter results SNG, or the firefighter brought in save the day?

The interview he did shortly after results has me leaning towards fire fighter, but thats just imho.

Yknow what I would really like to see? The 'no limitation of activities' chart up to 35 and 90 days

Doc, you would prefer positive data to be shared after the bell on a Friday?

The 'progression to severe disease or death' statistic has a p value of 0.051

I understand this is new data.

Woody, considering what others have had in terms of grants and funding and the data the company can put together between the numerous trials and independent study in of inf vs Covid, I am confident that if cash is required it will be forthcoming, w/o the need for another placing. (imho)

I agree with Axe, but have to be honest it's just my own speculation and not based on any inside info. Would be interested in hearing your thinking/source on this Axe.

They sure do capitalcity. What a waste of time this thread was...

It's really interesting that Pfizer pulled the plug on Paxlovid for hospitalized patients due to a lack of efficacy in their own trial, yet recovery is still looking at it.

Seems that links aren't working LSE atm...

"All the Oaks team have been fantastic at sending patients my way as we only had a small window for recruitment in the Synairgen study. Having one clinical system in primary care is a big advantage, so we are all inter-connected and the overlap helps with knowing patients and the people that could help them.

All the patients that we recruited to the study have since been re-consented as the Synairgen research team wanted to extend the study to examine the impact of long COVID-19 on patients.

It’s been a busy year for me as I also had around 30 other studies going on at the same time, but I feel very blessed to have had the opportunity to be involved in research. "

55 days between day 35 and day 90. What are we now, like 58ish since the 21 Feb RNS?

Found myself thinking today that it's a bit strange we haven't seen anything from the company re long covid. Nothing from P1-2-3 hospital, or from the UK home trial. I'd of thought they would surely have data on this from at least the earlier trials by now? Maybe I'm wrong and I missed it, but can't seem to find anything at all. Strange.

Ok, my bad Andy.

I'm no pharma professional, but I think a good way to market SNG to big pharma, governments and the scientific community could be by presenting a detailed analysis of SNG001 Vs Covid at a large Industry conference of some sort, that would have all of the big players in attendance.

Why so keen to change the subject Andy?

TBC, but producing just one active ingredient with a reusable delivery method bodes well scaling production with minimal cost. You can buy INFb on the internet for 50 bucks.

Further,, the company have proven the treatment can be successfully self administered by patients at home, which is a huge savings over any injected or intravenous administration.

Nice find Titania, thank you for sharing... Inhaled INFb mentioned a couple more times in the same paper as below:

"Another inhaled option is IFN, a family of proteins that display profound antiviral activity. Studies of genetic susceptibility to severe infection and natural autoantibodies against IFN-a have revealed that the severity of COVID-19 is highly dependent on the endogenous level of type 1 IFN (101, 102). Inhaled delivery of IFN-ß, which is not susceptible to antibody inhibition, has shown value in early-phase studies and is being assessed at a larger scale (103). The combination of ICS and IFN-ß could target both the excessive host response and the virus early in the disease, reducing viral burden and hospitalization as well as transmission."

And Futher, from the conclusion:

"We also must think beyond our current, limited field-of-view. Most of the current response has focused on preventing death in hospitalized patients. Effective treatments for earlier disease that can be deployed widely to prevent hospitalization have eluded us; oral and inhaled routes of delivery are important for mass deployment. These treatments are particularly important for less-wealthy countries in which hospital infrastructure is limited. Most conditions require combination therapy and we need to consider how the armamentarium can be used to maximal effect; this is likely to involve combining antiviral and immunomodulatory drugs. SARS-CoV-2 targeted antivirals are a clear gap, but host-directed antivirals and interventions based on specific cellular aspects of the inflammatory response may also be important. Host-directed antivirals may be particularly important because they are likely to have utility against many other viruses, and thus may prevent an epidemic turning into a pandemic."

I expect the first one is the more likely, but if it had been applied for in anticipation of positive sprinter results, it's quite a wait for 31 March.